New model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
BEERSE, Belgium, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, a worldwide leader in multiple myeloma, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI ® (teclistamab) plus daratumumab in patients with relapsed or refractory multiple myeloma…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- What Carson Families Are Looking for in Kids’ Birthday Party Places in 2026
- iQor Qares Raises More Than ₱5.8 Million at Charity Gala in Manila
- TechDigital Labs Introduces Enhanced SEO Audits for Websites, E-Commerce, and SaaS
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →